Angiotech gets FDA clearance for embolism filter

06/8/2009 | Boston Globe (tiered subscription model), The

Angiotech Pharmaceuticals has received marketing approval from the FDA for Option Inferior Vena Cava filter, which can be permanently or temporarily implanted to prevent periodic pulmonary embolism. The company expects the market for the device to reach about $300 million by 2012.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR